Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell’Italia Meridionale Multicenter Phase II Study

Publisher： Karger

E-ISSN： 1423-0232|79|5-6|415-422

ISSN： 0030-2414

Source： Oncology, Vol.79, Iss.5-6, 2011-04, pp. : 415-422

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 230-236

Karger

Access to resources Recommend Favorite

Randomized phase 2 study of pegylated SN‐38 (EZN‐2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4223-4230

John Wiley & Sons Inc

Access to resources Recommend Favorite

Multicenter Phase I Study of Irinotecan plus Raltitrexed in Patients with 5-Fluorouracil-Refractory Advanced Colorectal Cancer

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 42-47

Karger

Access to resources Recommend Favorite

A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan

By  

Oncology, Vol. 84, Iss. 4, 2013-01 ,pp. : 210-213

Karger

Access to resources Recommend Favorite

Cetuximab plus FOLFOX for Patients with Metastatic Colorectal Cancer with Poor Performance Status and/or Severe Tumor-Related Complications

By  

Case Reports in Oncology, Vol. 3, Iss. 2, 2010-07 ,pp. : 282-286

Karger

Access to resources Recommend Favorite